University of Greifswald

BASEL, Switzerland I October 23, 2024 I AMYRA Biotech AG (“AMYRA”), a company developing novel, oral digestive enzyme therapeutics for gastrointestinal diseases announced the peer-reviewed publication of its clinical proof-of-principle study with its lead product AMYNOPEP in Frontiers in Immunology – Nutritional Immunology ( https://www.frontiersin.org/journals/immunology/articles/10.3389/fimmu.2024.1425982/full ). AMYNOPEP is the first and only gluten-digesting enzyme combination that supports and enhances the activity of critical endogenous enzymes on the lining of the small intestine. AMYNOPEP is designed to break down hard-to-digest gluten peptides into harmless and absorbable single amino acids and dipeptides, thereby supporting individuals with gluten-related health disorders in avoiding exposure to inflammatory peptides. AMYRA’s first-in-human clinical study assessed gluten-digesting enzyme efficacy using high-resolution analytics and demonstrated in near-real-time that AMYNOPEP swiftly and significantly enhanced the digestion of proteolytically-resistant, immunogenic gluten peptides in healthy volunteers. A team of researchers from AMYRA and the University of Greifswald (Germany) evaluated AMYNOPEP’s digestive efficacy on the degradation of a long, proteolytically resistant gluten peptide known as the 33-mer, which has been associated with an adverse immune response in celiac disease. The digestion efficacy of AMYNOPEP on the 33-mer was first assessed in vitro , demonstrating end-to-end degradation of the gluten immunogenic peptide into single amino acids and dipeptides. These in vitro results were then validated in a crossover study of 14 healthy volunteers who received stable isotope-labelled 33-mer with and without AMYNOPEP. The study clearly showed that AMYNOPEP enhanced 33-mer digestion kinetics within minutes, significantly increasing levels of stable isotope-labelled amino acids detected in blood. Strikingly, AMYNOPEP improved 33-mer digestion even under “stress-test” conditions that included competing food substrates such as hydrolyzed whey protein and wheat gluten, revealing up to 3 times higher maximum concentrations of labelled amino acids in blood with AMYNOPEP compared to control. “The positive results of this proof-of-principle study pave the way for a new therapeutic enzyme paradigm leveraging specific exopeptidase combinations that support, enhance, or even replace the activity of critical endogenous enzymes lining the small intestine,” said Dr. Sulay Mourabit, CSO of AMYRA and co-lead author on the study. In the human gastrointestinal tract, most exopeptidases are found at the intestinal brush border membrane, which is sensitive to inflammatory damage. These exopeptidases are essential for completing protein digestion by cleaving peptides from end-to-end, generating absorbable amino acids. He added: “As single agents, exopeptidases are inefficient as they have limited substrate range, and we see this with DPP-IV supplements currently on the market. AMYRA specializes in developing unique combinations of exopeptidases with complementary and enhanced activity, designed to thoroughly break down proteolytically resistant food peptides. Ultimately, complex digestive diseases such as celiac may require a combination of treatment approaches. Given the critical role of the exopeptidase machinery in the human GI tract, and the vulnerability of the intestinal brush border membrane to chronic inflammatory damage, we’re excited to see the role that AMYNOPEP will play in digestive disease therapeutics.” “This is an encouraging and far-reaching proof-of-principle study demonstrating the validity and therapeutic relevance of our approach,” said Dr. Werner Tschollar, CEO and founder of AMYRA and senior author of the study. “As a next step, AMYRA is planning further clinical studies to investigate AMYNOPEP’s enzyme efficacy, immune response suppression, and symptom relief in patients with celiac disease. We strongly believe that supplementing the body with specific exopeptidases will prove to be a valuable adjunct therapy to the gluten-free diet, which alone represents a suboptimal solution.” About AMYRA Biotech AG AMYRA Biotech AG is a privately held biotech company developing novel therapeutic solutions for patients suffering from dietary peptide-driven disorders including celiac disease, gluten sensitivity, and other gastrointestinal disorders. The Company’s proprietary enzyme combinations have the unique capability of rapidly and systematically digesting proteolytically resistant gluten peptides from one end to the other, generating harmless and absorbable degradation products in the small intestine.  AMYRA is based in Basel, Switzerland. For further information, please visit www.amyra.com. About AMYNOPEP Several digestive enzyme supplements on the market and therapeutics under development seek to help the body break down hard-to-digest gluten peptides, which are known to trigger adverse reactions in individuals with gluten-related health disorders. The vast majority of these are endopeptidases that target gluten digestion in the stomach and generate smaller protein fragments (peptides) that may retain the ability to trigger an inflammatory response. In contrast, AMYNOPEP is a novel therapeutic enzyme principle based on specific combinations of exopeptidases that thoroughly degrade gluten peptides from end-to-end in the small intestine, generating individual, easily absorbable, and harmless amino acids and dipeptides that are incapable of triggering an immune response. AMYRA’s lead exopeptidase combination, AMYNOPEP, is capable of digesting proline-rich, hard-to-digest peptides found in foods such as gluten, which is notoriously linked to gastrointestinal distress. SOURCE: AMYRA Biotech

With regards to the AstraZeneca and Johnson & Johnson vaccines, the findings concretely implicate the adenovirus as the culprit behind rare cases of vaccine-induced immune thrombocytopenia and thrombosis. The rare, deadly blood clots triggered by an autoimmune response to the COVID-19 vaccines from Johnson & Johnson and AstraZeneca seem to be caused by a gene that’s also responsible for an unusual but almost identical reaction to the virus that causes the common cold. The findings could have implications for future vaccines.  In a letter published May 15 in The New England Journal of Medicine, an international team of scientists explained that people who carry certain variants of a gene called IGLV3-21*02 are predisposed to developing both vaccine-induced immune thrombocytopenia and thrombosis (VITT) and the same type of reaction after infection with the adenovirus. Both the J&J and AstraZeneca vaccines are delivered to the body in adenovirus vectors, which explains why the etiology of the conditions is the same.  “Our findings have the important clinical implication that lessons learned from VITT are applicable to rare cases of blood clotting after adenovirus infections, as well as having implications for vaccine development," Tom Gordon, M.D., Ph.D., of Flinders University, who led the co-study, said in a press release. Theodore Warkentin, M.D. from McMaster University in Canada and Andreas Greinacher, M.D., from Greifswald University in Germany also led the work.  AstraZeneca’s vaccine, Vaxzevria, was dogged by reports of VITT not long after the shot rolled out in Europe. Soon after, news of VITT in six U.S. patients who took the J&J vaccine emerged as well, prompting officials to pause it to investigate and later restrict its use. It was removed from the market entirely two years later. AstraZeneca’s shot remained available in some parts of Europe until May 2024, when the company requested its marketing approval be revoked due to a decline in demand.  As of May 2023, the same month J&J’s vaccine was pulled, there had been 60 cases of VITT reported in the U.S., including nine deaths. The last count for VITT cases related to AstraZeneca’s vaccine in the U.K. before it was taken off the market was 455, with 81 deaths, according to the U.K.'s healthcare watchdog the Medicines and Healthcare products Regulatory Agency.  The reactions are caused by antibodies against the protein platelet factor 4, or PF4, a protein involved in blood clotting. In 2022, Gordon and his colleagues used a screening method called antibody proteomics to show that antibodies expressed by a variant of IGLV3-21*02 targeted PF4. Genetic analysis of five patients who developed VITT after getting the AstraZeneca vaccine showed that all of them had this gene variant.  Then, in 2023, another research team reported that adenovirus infection led to the same anti-PF4 antibodies and immune thrombocytopenia and thrombosis. The pathogenesis was identical to VITT; this was the first signal of an “anti-PF4 disorder,” as the researchers called it, that might share its etiology.  The two groups teamed up to validate their hypotheses. When they analyzed the structure of the anti-PF4 antibodies from patients in each group and superimposed them, they found they were “extremely similar,” as they wrote in the NEJM letter.  “Such an extraordinary level of autoantibody fingerprint identity between two disorders—at the level of patient-derived antibodies—strongly indicates that VITT and the anti-PF4 disorder that is associated with adenoviral infection are a distinct class of adverse immune responses associated with viral (presumably, adenoviral) structures,” the researchers wrote.  With regards to the AstraZeneca and J&J vaccines, the findings concretely implicate the adenovirus as the cause of VITT rather than other ingredients. But while the researchers know that the immune response to the virus triggers the creation of antibodies to PF4, they still need to identify the antigen, or the proteins or sugars on the virus, that stimulates their creation. This would potentially enable them to genetically engineer the adenovirus vector so it doesn’t have the antigen and, thus, makes adenovirus-based vaccines safer. The team behind the new NEJM paper is currently investigating the antigenic epitope, or the part of the antigen the immune system recognizes, Gordon confirmed to Fierce Biotech Research in an email.  Previously, the Flinders scientists said it may be possible to create a genetic test that can identify patients at risk of VITT as well as to come up with a therapy that neutralizes the anti-PF4 antibodies.  In a statement to Bloomberg earlier this week, an AstraZeneca spokesperson said the company “welcomes any further examination of the possible underlying mechanism of thrombosis with thrombocytopenia syndrome.” J&J told the outlet in an email that it supports the research as well and that “more data are needed to fully understand potential factors that may be associated with this rare event.” 

CARBIOS Group’s solid financial structure: cash position of €192 million on December 31, 2023Construction progress of world’s first PET1 biorecycling plant in France: in line with delivery targets for customers in 2026Licensing: international sales teams deployed in more than ten countries, with several partnerships feasible for 2024 Clermont-Ferrand, France, April 11, 2024 (6:45 a.m. CEST) - CARBIOS (Euronext Growth Paris: ALCRB), a biotech company developing and industrializing biological solutions to reinvent the life cycle of plastic and textiles, today reported its operating and financial results for the financial year 2023. The financial statements as of December 31, 2023, were approved by the Company’s Board of Directors at their meeting on April 10, 2024. Emmanuel Ladent, CEO of CARBIOS: “2023 was marked by major scientific and operational achievements, most prominently, the start of the construction, in France, of the world’s first industrial PET biorecycling plant which is due to go into production in 2026 and will serve the many customers who expect our products. We also signed a mutually exclusive alliance with Novonesis ensuring enzyme supply for our Longlaville plant and all future plants operated under license. In addition, we reached an important milestone for the recycling of polyester textiles with the development and implementation of a fully automated and integrated textile preparation line. I would like to thank the commitment of our employees, as well as all our partners’ contributions in making CARBIOS a future world leader in the r-PET market.” Pascal Bricout, Chief of Strategy and Financial Officer of CARBIOS: “In fiscal year 2023, we consolidated our financial structure to support the industrial and commercial deployment of our technologies and accelerate our R&D on other polymer families, notably polyamides and polyolefins. We successfully completed a capital increase with preferential subscription rights for a gross amount of €141 million, the largest fundraising on Euronext Growth since 2015. In addition, we were granted funding totaling €54 million from French State via France 2030 and Grand-Est Region, of the majority of which will be allocated to the construction of our plant in Longlaville. The official groundbreaking ceremony will take place on 25 April. We now have the resources required to press ahead with the construction of our first plant and ensure the commercial and international deployment of our activities.” A webcast and conference call will take place today at 11:00 am (CEST) Emmanuel LADENT – CEO / Pascal BRICOUT – Chief of Strategy and Finance Access to the webcast: https://edge.media-server.com/mmc/p/cyrcdmu8 France Dial-in: +33 170918704 UK Dial-in: +44 1 212818004 US Dial-in: +1 718 7058796 2023 Financial highlights The consolidated financial statements of the Company as of December 31, 2023, are presented in accordance with International Financial Reporting Standards (IFRS) as issued by the International Accounting Standards Board (IASB) and adopted by the European Union. For 2022 and 2023, these IFRS consolidated financial statements include the financial statements of CARBIOS, the parent company, and the financial statements of its fully integrated subsidiaries Carbiolice and CARBIOS 542. The group formed by CARBIOS, Carbiolice and CARBIOS 54 is hereinafter referred to as the “Group”. These IFRS financial statements for the Group have been prepared to provide high quality information in line with that of similar companies and based on international standards. Consolidated Statement of income Consolidated statement of income (in thousand euros) December31, 2023December 31, 2022 12 months12 monthsIncome 2470Net Research and Development expenses (10,958)(12,993) Research and Development expenses (18,830) (19,057) Subsidies and other income from activities 5,385 4,776 Capitalisation of development costs 2,487 1,287 Sales and marketing expenses (5,809)(4,373)General and administrative expenses (12,134)(8,807)Operating expenses (28,902)(26,173)Other operating income and expenses -2Operating income (28,878)(26,101) Financial income 1,655(1,640)Income before tax (27,224)(27,741)Income tax --Share and profit (loss) of equity affiliates -- Net income (loss) for the period (27,224)(27,741) Income according to IFRS 15 standards For the financial years 2022 and 2023, income accounted under IFRS 15 is related to feasibility studies, tests, and research services with performance obligation, as well as deliveries of raw materials and samples of CARBIOS Active by Carbiolice. As of December 31, 2023, the Group’s income stood at €24 thousand, compared to €70 thousand for the year ended December 31, 2022. Current operating expenses With regards to the presentation of its IFRS consolidated statements, the Group shows a statement of income by destination. Thus, current operating expenses are categorized and presented as: Net Research and Development expenses, Sales and Marketing expenses, as well as General and Administrative expenses. Operating expenses stood at €28,902 thousand for 2023, compared to €26,173 thousand in 2022. To support the growth of its activities, the average number of employees within the Group increased from 104 in 2022 to 134 in 2023. Net Research and Development expenses: The Group pursued its research and development efforts on all its proprietary pipeline of innovations and notably on its biorecycling technology for PET plastic and polyester fibers. For 2023, the Group’s Net R&D expenses stood at €10,958 thousand, compared to €12,993 thousand for 2022. For FY 2023: On R&D, the Group spent €18,958 thousand. The slight decrease in R&D expenses is mainly due to the launch of the OPTI-ZYME project financed by ADEME, under which the Group’s academic partners are funded directly through the project. In addition, as the plant construction project has progressed, engineering costs are no longer accounted as expenses but capitalized directly to fixed asset accounts. Also, to successfully complete its R&D and industrial projects, the Company is continuing to strengthen its teams, which explains the increase in personnel costs.On Subsidies and other income from operations, the Group recorded €5,385 thousand, partially offsetting its R&D expenses. This item includes notably research tax credits to be received of respectively €2,543 thousand for CARBIOS and €672 thousand for Carbiolice in 2023 (as opposed to respectively €2,538 thousand and €655 thousand in 2022), as well as grants received during the year linked to the launch of the OPTI-ZYME project financed by ADEME. Finally, the Group has capitalized €2,487 thousand development expenses related to the Company’s PET enzymatic recycling project in 2023. Sales and Marketing expenses: Sales and marketing expenses stood at €5,809 thousand in 2023, compared to €4,373 thousand in 2022. This increase mainly comes from strengthened efforts to address market demand and sell licences in a near future. The Group is also continuing its structuring work with a reinforcement of its teams to achieve its development goals in France and internationally. General and Administrative expenses: General and administrative expenses stood at €12,134 thousand in 2023, as opposed to €8,807 thousand in 2022. This increase is mainly due to the strengthening of the teams dedicated to the Longlaville plant construction and increased use of external consulting services to continue structuring the Group in a variety of areas (recruitment, QHSE, CSR, IT, etc.) Balance Sheet items Consolidated statement of financial position(in thousand euros) December31, 2023 December31, 2022 12 months 12 months ASSETS Goodwill 20,583 20,583 Intangible assets 21,874 22,457 Tangible assets 49,199 24,965 Right-of-use assets 6,175 6,765 Financial assets 1,219 906 Non-current assets 99,049 75,674 Trade receivables 6 57 Inventory 511 - Other current assets 10,621 7,670 Cash and cash equivalents 191,821 100,557 Current assets 202,009 108,284 Total assets 302,009 183,959 Consolidated statement of financial position (in thousand euros) December31, 2023 December31, 2022 EQUITY AND LIABILITIES Share capital 11,786 7,870 Share and contribution premium 276,569 146,968 Consolidated reserves (2,900) (5,482) Retained earnings (23,917) 3,826 Net income – share attributable to equity holders of the parent company (27,224) (27,741) Shareholders’ equity 234,314 125,441 Provisions – Non-current portion 216 184 Loans and financial liabilities – Non-current portion 39,226 35,395 Lease liabilities – Non-current portion 4,639 5,142 Other liabilities – Non-current portion 449 546 Deferred tax liabilities 1,694 1,694 Non-current liabilities 46,224 42,961 Provisions - Current portion - - Loans and financial liabilities – Current portion 3,524 2,782 Lease liabilities – Current portion 1,232 1,346 Trade payables 4,829 4,021 Other current liabilities 11,888 7,408 Current liabilities 21,472 15,557 Total liabilities and equity 302,009 183,959 As of December 31, 2023, cash and cash equivalents amounted to €192 million, compared to €101 million for the year ended December 31, 2022. The other key balance sheet items as of December 31, 2023 are: €20,6 million corresponding to the Goodwill calculated between the market value of Carbiolice and the net assets acquired; the impairment tests carried out in 2023 do not call this amount into question.Intangible assets for a net book value of €21.9 million for the year ended December 31, 2023. Pursuing on its active policy of securing its Intellectual Property, CARBIOS continued to enrich its IP portfolio with the filing of 5 new patent families. The Group’s intellectual property portfolio at the end of 2023 included 58 patent families.As a result of the full integration of Carbiolice in 2021, €22.3 million were also recognized for the purchase price of Carbiolice, with a net amortization position of €18 million as of December 31, 2023, including: €10.1 million net (€12.5 million gross) for the technology license (or “reacquired rights”). Under IFRS 3, the technology license between CARBIOS and Carbiolice is assimilated to a pre-existing relationship giving rise to the recognition of a “reacquired rights” asset that has been valued using the expected cash flow method; and€7.9 million net (€9.8 million gross) market value of the acquired technology (Masterbatch) valued using the royalty and restoration cost method. Tangible assets for a net book value of €49.2 million, as compared to €25 million for the year ended December 31, 2022. This strong increase is mainly due to: €21 million investment related to the construction project of the first PET biorecycling plant through CARBIOS 54;continued investment in the industrial demonstration facility. These tangible assets also include leasebacks relating to the industrial demonstration facility. As of December 31, 2023, the operation covers €4.3 million of equipment depreciated over 10 years, in addition to the €1.5 million for the previous year; and€2.1 million invested in renovating the building housing the production line of Carbiolice and the textile preparation line, at the Cataroux site in Clermont-Ferrand. Rights-of-use asset for a net book value of €6.2 million corresponding to the market value of the tangible and intangible assets benefiting to the Group through its various lease contracts. In return, “lease debts” are recorded on the liabilities side of the balance sheet as financing for these assets; andShareholder’s equity of €234.3 million, including the net proceeds of the €141 million capital increase successfully completed in July 2023 with French and International investors, as compared to €125.4 million for the year ended December 31, 2022. Cash flow statement Consolidated cash flow statement (in thousand euros) December31, 2023 December31, 2022 Cash at beginning of year 100,556 104,956 Cash flow from operating activities (22,589) (21,820)Cash flow from investing activities (22,391) (9,327)Cash flow from financing activities 136,246 26,747 Change in cash position 91,265 (4,398) Cash at end of year 191,821 100,557 Benefiting from the net proceeds of the €141 million raised in 2023, the Group closed out with a net cash position of €192 million at year-end 2023, enabling it to pursue current developments beyond the next 12 months. FY 2023 and post-closing highlights Construction of the world’s first industrial PET biorecycling plant in France In fiscal year 2023, we have established the necessary partnerships to successfully build the world's first PET biorecycling plant in France. This industrial plant, which is currently under construction in Longlaville (permit granted in October 2023 and groundbreaking ceremony to be held on April 25, 2024) is located at the borders of Luxembourg, Germany and Belgium, some of the most advanced waste-sorting countries. It is designed to process 50,000 tons of PET waste annually, equivalent to 2 billion bottles or 2.5 billion food trays. This plant will also serve to bolster the Company's business model of licensing its technology to manufacturers who will build their own plants, as well as reinforce the Company's know-how in its industrial and commercial deployment strategy through international licensing. In June 2023, we signed a non-binding Memorandum of Understanding (“MOU”) with Indorama Ventures, with a view to acquiring a minority stake in this first PET biorecycling plant. In October 2023, we were granted the building permit and operating authorization for the PET biorecycling plant, allowing construction to start. In addition, in February 2024, we completed the acquisition from Indorama Ventures of a 13.7-hectare site adjacent to their existing PET production plant in Longlaville. The land area acquired by CARBIOS gives the possibility to double the facility's capacity. By simultaneously acquiring construction and operating permits, construction work as well as recruitment and training of plant staff can continue as planned. The state-of-the-art facility will pave the way for PET circular economy by providing an industrial-scale enzymatic recycling solution for PET waste. Our PET recycling technology offers an alternative raw material to virgin fossil-based monomers, allowing PET producers, chemical companies, waste management firms, public entities, and brands to meet regulatory requirements and fulfill given sustainability commitments. In February 2024, CARBIOS and De Smet Engineers & Contractors (DSEC) announced their collaboration to spearhead the construction of the plant. Under the agreement, De Smet has been entrusted with the project management and detailed engineering, including procurement assistance and CARBIOS partners’ management, to ensure the execution of the plant's construction in Longlaville, France. Financing of plant In May 2023, CARBIOS announced that its project has been selected by the French government for funding for an amount of €30 million from the French State via France 2030 and €12.5 million from the Grand-Est Region3. Alongside this support, CARBIOS has been granted total funding of €11.4 million from the French State as part of France 2030, of which €8.2 million directly for CARBIOS (€5 million in repayable advances) and €3.2 million for its academic partners INRAE, INSA and CNRS via the TWB and TBI joint service and research units. This funding will enable the Group to continue its research into the optimization and continuous improvement of CARBIOS’ enzymatic technologies. In July 2023, CARBIOS announced the success of its capital increase in cash with preferential subscription rights (“PSR”) maintained for a gross amount of approximately €141 million4. Approximately 85% of the net proceeds of this capital increase are to be used to finance the construction of the industrial PET biorecycling plant, for which the investment was estimated in June 2023 at around €230 million (FEL 3). Textile preparation line In October 2023, CARBIOS inaugurated its textile preparation line at our demonstration plant in Clermont-Ferrand. Polyester textiles account for 2/3 of the global PET market of around 100 million tons. Only 13% of textile waste is currently recycled, and only 1% is recycled "fiber-to-fiber"5,6. To streamline the textile preparation phase, CARBIOS has developed a fully integrated and automated line that transforms textile waste from used garments or cutting scraps into raw material suitable for depolymerization with its enzymatic biorecycling process. This patented line integrates all preparation stages (shredding and extraction of hard points such as buttons or fasteners), and provides CARBIOS with a high-performance, scalable development tool. Other operational highlights Strategic alliance with Novonesis In January 2023, CARBIOS strengthened its strategic partnership with Novonesis by signing an exclusive and long-term agreement which ensures the production and supply of CARBIOS’ proprietary PET degrading enzymes at industrial scale for our first plant, as well as for our future licensees. Licensing documentation ready In April 2023, we finalized the engineering documentation7 enabling us to provide our licensees with the necessary information for future industrial plants. This new industrial milestone on schedule in the deployment of our PET biorecycling technology is the result of our successful operations conducted in our demonstration plant and is the starting point to enter first licensing agreements in 2024. It will enable CARBIOS’ future licensees to reliably engineer, construct and operate their own PET biorecycling facilities. Supply agreements secured with Citeo and Landbell Group In April 2023, we secured a first supply agreement with Citeo for our PET biorecycling plant. This long-term agreement covers the supply of PET waste from multilayer and monolayer trays. This PET waste will be recycled in our industrial plant, which is due to go into production in 2026. In February 2024, CARBIOS and Landbell Group, a leading provider for compliance solutions and global operator of more than 40 takeback schemes, announce the signing of a non-binding Memorandum of Understanding (MOU) to supply 15kt/year of post-consumer PET waste to CARBIOS' first commercial plant in Longlaville starting 2026. Through the partnership with Landbell Group in Germany, the supply agreement with Citeo in France and the MOU with Indorama Ventures, CARBIOS will have covered over 70% of its feedstock required for the 50kt/year capacity when its first commercial plant in Longlaville, France, will operate at full capacity. Textile consortium In February 2023, PVH Corp., a leading fashion company joined our fiber-to-fiber consortium founded by CARBIOS with On, Patagonia, PUMA, and Salomon. Committed to accelerating the transition of the textile industry toward a circular economy, consortium members collaborate to test and enhance CARBIOS’ breakthrough biological recycling technology on their own products. The common goal of the consortium members is to create real circularity in this industry by innovating to recycle fibers from one product into another and so reduce the problem of textile waste in a collaborative approach that helps create a more sustainable future. Ellen MacArthur Foundation and Paris Good Fashion In March 2023, CARBIOS became a member of the Ellen MacArthur Foundation’s Network. CARBIOS shares the Foundation’s commitment to accelerate the transition to a circular economy, especially in the areas of plastic and fashion. By joining the Ellen MacArthur Foundation’s Network, CARBIOS will connect with other leaders within the Foundation’s leading circular economy network of businesses, policymakers, academia, innovators, and thought leaders worldwide. In March 2024, CARBIOS became a member of Paris Good Fashion, the association that unites over 100 French players in the sector - brands, designers and experts - around their commitment to sustainable fashion. CARBIOS is the first recycling technology supplier to join, demonstrating the importance given to recycling to achieve textile circularity. CARBIOS will be particularly involved in the association's project to set up a working group dedicated to the development of a "fiber-to-fiber" industry, one of Paris Good Fashion's top priorities over the next five years. While only 1% of textiles are currently recycled fiber-to-fiber (circular), this working group will identify levers for significantly increasing the share of recycled fibers in the industry. Technology and IP update In February 2023, CARBIOS successfully validated the final key stage of the CE-PET research project supported by the French State as part of the Investments for the Future Program, now integrated into France 2030, and operated by ADEME, and for which CARBIOS was coordinator alongside its academic partner INRAE -TWB (Toulouse Biotechnology Institute). The CE-PET project, which lasted four years, confirmed CARBIOS ability to enzymatically recycle complex waste to produce bottles and fibers. In March 2023, biotechnology researchers from CARBIOS and its academic partner Toulouse Biotechnology Institute (TBI), as well as two eminent professors in polymer science from the University of Bordeaux published in Chemical Reviews an article entitled “Enzymes’ power for plastics degradation”. The article is a comprehensive and critical review of research published to date on the enzymatic degradation of all types of plastics (PET, PLA, polyolefins, polyurethanes, polyamides) and includes almost 700 references. In April 2023, we announced the development of an ultra-high throughput microfluidic screening of PET-depolymerizing enzymes in partnership with the Paul Pascal Research Centre (a joint research unit of the CNRS and the University of Bordeaux, which specializes in microfluidics). This cutting-edge technology enables the screening of millions of enzymes in just one day, speeding up the process to optimize enzymes breaking down PET. This competitive advantage enables CARBIOS to reduce the time between the R&D phase and the production of its proprietary enzymes, and therefore to develop concrete solutions to plastic pollution even faster. Also, in October 2023, CARBIOS announced the publication in ACS Catalysis of an article entitled "Assessment of Four Engineered PET Degrading Enzymes Considering Large-Scale Industrial Applications". The article demonstrates that under industrial conditions CARBIOS' enzyme LCCICCG (published in Nature in 2020) outperforms all three competitors considered most promising in scientific literature: two variants of the IsPETase enzyme produced by Ideonella sakaiensis described by the University of Manchester and the University of Austin (Texas) and a variant of PES-H1 (also known as PHL7) described by the University of Greifswald. As of today, CARBIOS’ intellectual property portfolio covered 398 titles worldwide divided into 58 patent families for its innovation in enzymatic recycling of PET plastics and fibers, and its PLA biodegradation technology. CSR policy In June 2023, we integrated our Purpose into the bylaws of the Company, as permitted by the PACTE Act of 2019, following the vote at the Annual General Meeting held on 22 June 2023, namely "to generate a positive and significant social, societal and environmental impact in the conduct of its activities". This Purpose underpins CARBIOS' business, which provides solutions to the environmental emergency of tackling plastic pollution. In December 2023, we published our second Sustainability Report. Like the first, this report is not subject to any publication obligation for the company but confirms CARBIOS' commitment and desire for transparency in terms of environmental, social and governance (ESG) initiatives. Going beyond the industrial development of its innovative technologies, the company shares its progress and ambitions for the future. In April 2024, CARBIOS announced the success of its first employee share scheme for all employees of the Group who are members of the savings plan in France. Launched on 12 February 2024, 123 employees subscribed, representing 88.49% of the eligible workforce, thereby enabling employees to participate in the Group’s growth and performance. As a result, CARBIOS’ employee share ownership, within the meaning of the Article L. 225-102 of the French Commercial Code, now stands at around 0,08% of the share capital. Strengthening governance Change in the Board of Directors In February 2023, CARBIOS announced the cooptation, within its Board of Directors, of Karine Auclair, professor of Chemistry at McGill University, Mateus Schreiner Garcez Lopes, Global Director for Energy Transition and Investments at Raizen, Amandine De Souza, General Manager of leboncoin and Sandrine Conseiller, CEO of De Beers Brands and former CEO of Aigle, as independent members of CARBIOS’ Board of Directors. To date, the Company has seven independent Directors, i.e. 63.64% of the total number of Directors. Change in the Executive Committee In October 2023, we strengthened our leadership team with the appointment of Bénédicte Garbil as Senior Vice President of Corporate Affairs, Sustainability and Communication. As a member of the CARBIOS Executive Committee, Bénédicte Garbil oversees three strategic areas: Public Affairs, Corporate Affairs, and Sustainability. In her Corporate Affairs role, she supervises Communication, Regulatory, Project Management, and Innovation Funding functions. In her Sustainability role, she oversees CSR8, QHSE9, and LCA10 functions. Awards In May 2023, CARBIOS was selected to represent French innovation at the 6th “Choose France” Summit at the Château de Versailles. “Choose France” is an international business summit dedicated to the attractiveness of France launched at the initiative of the French President, Emmanuel Macron. On this occasion, CARBIOS announced that it had joined the Coq Vert community launched by Bpifrance in partnership with ADEME and the Ministry of Ecological Transition, to connect with other environmentally committed business leaders and advance its international deployment. In November 2023, together with our partner L'Oréal, the world’s leading beauty player, we won the "Pioneer Awards" in the Industry category, presented by the Solar Impulse Foundation at the first World Alliance Summit. This prestigious prize was awarded to CARBIOS for its enzymatic PET recycling solution, labeled "Efficient Solution" by the Solar Impulse Foundation since 2019, and to L'Oréal for using this breakthrough technology for the first time in a cosmetics bottle prototype. CARBIOS' solution offers brands an alternative to petro-sourced plastic that helps them meet their sustainability commitments. In March 2024, CARBIOS has been awarded the Small & Mid Cap 2023 Secondary Transaction award by Euronext. This award recognizes the success of CARBIOS’ €141 million rights issue, which was the largest transaction carried out on Euronext Growth since 2015. Outlook – confirmation of industrial and commercial objectives Given the significant progress made by the Group during 2023 and the success of the financing operation closed in July 2023 as well as the received grants, CARBIOS confirms its operating targets and the provisional calendar of the industrial and commercial deployment of its PET biorecycling technology11. 2024 • Construction of the Longlaville plant further to permits obtained in October 20232024 • Recruitment of plant operations team and training at demonstration facility2026 • First significant deliveries to clients Alongside this project, CARBIOS aims to sign its first licensing contracts for its PET biorecycling technology in 2024. ### About CARBIOS: CARBIOS is a biotech company developing and industrializing biological solutions to reinvent the life cycle of plastic and textiles. Inspired by nature, CARBIOS develops enzyme-based processes to break down plastic with a mission to avoid plastic and textile pollution, and accelerate the transition to a circular economy. Its two disruptive technologies for the biorecycling of PET and the biodegradation of PLA are reaching industrial and commercial scale. Its biorecycling demonstration plant has been operational since 2021 and a first industrial plant is currently under construction in partnership with Indorama Ventures. CARBIOS has received scientific recognition, notably with the cover of Nature, and is supported by prestigious brands in the cosmetics, Food & Beverage and apparel industries to enhance their products’ recyclability and circularity. Nestlé Waters, PepsiCo and Suntory Beverage & Food Europe are members of a packaging consortium founded by CARBIOS and L’Oréal. On, Patagonia, PUMA, PVH Corp. and Salomon collaborate with CARBIOS in a textile consortium.Visit www.CARBIOS.com/en to find out more about biotechnology powering plastic and textile circularity.Twitter: CARBIOS / LinkedIn: CARBIOS / Instagram: insideCARBIOS Information on CARBIOS shares: ISIN Code FR0011648716Ticker Code Euronext Growth: ALCRBLEI: 969500M2RCIWO4NO5F08 CARBIOS, founded in 2011 by Truffle Capital, is eligible for the PEA-PME, a government program allowing French residents investing in SMEs to benefit from income tax rebates. Disclaimer on forward-looking statements and risk factors:This press release contains forward-looking statements, not historical data, and should not be construed as a guarantee that the facts and data stated will occur. These forward-looking statements are based on data, assumptions and estimates considered reasonable by CARBIOS. CARBIOS operates in a competitive and rapidly evolving environment. It is therefore not in a position to anticipate all risks, uncertainties or other factors that may affect its business, their potential impact on its business or the extent to which the materialization of a risk or combination of risks could lead to results that differ significantly from those mentioned in any forward-looking statement. CARBIOS draws your attention to the fact that forward-looking statements are in no way a guarantee of its future performance and that its actual financial position, results and cash flows and the development of the sector in which CARBIOS operates may differ significantly from those proposed or suggested by the forward-looking statements contained in this document. In addition, even if CARBIOS’ financial position, results, cash flows and developments in the industry in which it operates are consistent with the forward-looking information contained in this document, such results or developments may not be a reliable indication of CARBIOS’ future results or developments. Readers are advised to carefully consider the risk factors described in the Universal registration document filed with the French Market Authority (“AMF”), as well as in the half-year financial report available free of charge on the Company’s website. Should all or any part of these risk factors materialize or others, in no case whatsoever will CARBIOS be liable to anyone for any decision made or action taken in conjunction with the information and/or statements in this press release or for any related damages. This information is given only as of the date of this press release. CARBIOS makes no commitment to publish updates to this information or on the assumptions on which it is based, except in accordance with any legal or regulatory obligation applicable to it. For additional information, please contact: CARBIOSPress Relations (France)Press Relations (U.S)Press Relations (DACH & UK)Melissa FlauraudIconicRooney PartnersMC ServicesPress RelationsMarie-Virginie KleinKate L. BarretteAnne-HenneckeMelissa.flauraud@corbios.commvk@iconic-conseil.comkbarrette@rooneyco.comcarbios@mc-services.eu+33 (0)6 30 26 50 04+33 (0)1 44 14 99 96+1 212 223 0561+49 (0)211 529 252 22Benjamin Audebert Investor Relations contact@carbios.com +33 (0)4 73 86 51 76 This press release does not constitute and cannot be regarded as constituting an offer to the public, an offer to sell or a subscription offer or as a solicitation to solicit a buy or sell order in any country. Translation for information purposes only. In case of discrepancy between the French and the English version of this press release, the French version shall prevail. 1 PET = polyethylene terephthalate2 Wholly-owned subsidiary of Carbios for its industrial operations in Longlaville3 The implementation of this funding is conditional to the European Commission's approval of the corresponding state aid scheme, followed by the conclusion of national aid agreements.4 Further information on the capital increase, successfully completed in July 2023, can be found in the prospectus approved by the Autorité des marchés financiers (AMF) on June 21, 2023, under number 23-236, which is available free of charge from the CARBIOS (https://investir.CARBIOS.com) and the AMF (www.amf-france.org/fr) websites. 5 Ellen MacArthur Foundation, 20176 Fiber-to-fiber recycling transforms textile waste into new fibers for clothing and textiles, with no loss in quality7 Technological Information Summary8 CSR = Corporate Social Responsibility9 QHSE = Quality, Health, Security, Environment10 LCA = Life Cycle Analysis11 Estimated dates subject to the terms remaining to be defined for the collaboration between CARBIOS and Indorama Ventures Attachment 2024 04 11_PR_FY Results 2023 Final